Sentences with phrase «treatment of the central nervous system»

About Alkermes plc Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases.

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases.

It focuses on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders.

ACADIA Pharmaceuticals Inc. is focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders.

Supernus Pharmaceuticals, Inc. develops and commercializes products for the treatment of central nervous system.

Not exact matches

For example, MethylGene Inc. (TSX: MYG) is focusing on cancer treatment, biOasis Technologies Inc. (TSXV: BTI) is pursuing research on disorders of the central nervous system, and Cipher Pharmaceuticals Inc. (TSX: DND) is working on a treatment for acne - related conditions.

When it comes to medical treatment, the brain and central nervous system remain the darkest, most forbidding frontiers in the human body — and yet our knowledge of how the brain and mind actually work seems to be growing by leaps each year.

Palm Oil - Derived Natural Vitamin E a-Tocotrienol in Brain Health and Disease: Scientific literature evaluating the therapeutic potential of tocotrienols (type of vitamin E found in abundance in palm fruit oil) for neurodegenerative disorders of the central nervous system, cancer treatment, and hypercholesterolemia.

In the course of a study conducted throughout Germany, medical professionals have compared different treatment methods for Neuromyelitis optica, an inflammatory disease of the central nervous system.

The N2B patch project is supported financially by the EU within the scope of the tender procedure «Biomaterials for diagnosis and treatment of demyelination disorders of the central nervous system.»

Treatment with an investigational CAR T - cell therapy induced complete remission of a brain metastasis of the difficult - to - treat tumor diffuse large - B - cell lymphoma (DLBCL), which had become resistant to chemotherapy — the first report of a response to CAR T - cells in a central nervous system lymphoma.

Due to the central nervous system origins of fibromyalgia pain, Clauw said treatments with opioids or other narcotic analgesics usually are not effective because they do not reduce the activity of neurotransmitters in the brain.

The central nervous system (CNS) was the most frequent treatment site at four of the seven institutions, comprising 25 to 65 percent of treated cases across the facilities.

And experts report that Xyrem, a central nervous system depressant, has revolutionized the treatment of cataplexy.

«Some GPCRs, for instance, are targeted by neurotransmitters, and their functions are compromised in diseases of the central nervous system, so it is possible that optical switches could also be of interest in the treatment of conditions such as depression or epilepsy.

Ritalin, the brand name for methylphenidate, a central nervous system stimulant used in the treatment of attention deficit hyperactivity disorder, is a growing problem among college students who use it without a prescription as a so - called «study enhancer.»

While toxicity during induction is still of concern, especially in the elderly patients, we conclude from these data that de-escalation of induction therapy in elderly primary central nervous system lymphoma patients followed by maintenance treatment seems to be a promising treatment strategy.

The study, led by researchers at the University of Cambridge, is a step towards developing personalised treatments based on a patient's own skin cells for diseases of the central nervous system (CNS).

1/8/2008 UCSD Clinical Trial to Assess Effects of Drug Regimens on HIV - Related Neuro - Cognitive Impairment A clinical trial is being conducted by researchers at UCSD's HIV Neurobehavioral Research Center (HNRC) to discern which antiretroviral treatments are most effective in treating HIV - related disease in the brain and central nervous system.

These hit compounds contained bioactive molecules that are used as anti-cancer, anti-bacterial, and contraceptive agents, hormones, vitamins, as well as for the treatment of diseases related to the central nervous system, digestive system, heart and skin.

• Patients must have adequate coagulation (international normalized ratio (INR) or prothrombin time (PT), partial thromboplastin time (PTT) ≤ 1.5 times ULN) • Adequate liver function (total bilirubin ≤ 1.5 times the ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN Exclusion Criteria: • Presence of active / uncontrolled central nervous system involvement • History of clinically significant cardiac disease; uncontrolled hypertension • Left ventricular ejection fraction (LVEF) < 45 % • Allogeneic stem cell transplant within 100 days before first dose of study drug • Known history of human immunodeficiency virus (HIV) infection • Chronic or active hepatitis B or C, requiring antiviral therapy • Evidence of history of bleeding disorder, dialysis, or coexisting cancer that is distinct in primary site or histology from the cancer evaluated in this study • Serious, uncontrolled infection • Unresolved chronic toxicity > grade 1 from prior therapy • Use of strong CYP3A4 inhibitors or strong inducers within 7 days prior to the start of study treatment and for the duration of the study

Paris, France, April 3, 2018, 5.35 pm CET — GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA - PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced topline results from the REVERSE Phase III clinical trial evaluating the safety and efficacy of a single intravitreal injection of GS010 (rAAV2 / 2 - ND 4) in 37 subjects whose visual loss due to 11778 - ND4 Leber Hereditary Optic Neuropathy (LHON) commenced between 6 and 12 months prior to study treatment.

Thus, the lab's approach may hold great promise for potential treatment of (neuro) inflammation - related human diseases both in and outside the central nervous system.

The present studies provide multiple novel findings relevant to the development of astrocyte transplantation therapies for treatment of the injured or diseased central nervous system.

In Stiff Person Syndrome, which is a rare autoimmune disease in the central nervous system with autoantibodies targeting glutamic acid decarboxylase (GAD65), the humoral autoimmune response was shown to consist of a Rituximab - sensitive part rapidly cleared after treatment, and a Rituximab - resistant part from long - lived and persistent plasma cells acting as a reservoir for secretion of autoantibodies.

AveXis, Inc. and Genethon today announced they have entered into an exclusive, worldwide license agreement for in vivo gene therapy delivery of AAV9 vector into the central nervous system (CNS) for the treatment of spinal muscular atrophy (SMA).

Development of treatments for diseases of the central nervous system, Feng says, «has essentially stalled.»

Treatment of disorders of the central nervous system including malignant, benign and functional diseases, Stereotactic radiosurgery (SRS) via both Gamma Knife and Linear Accelerator platforms, Stereotactic ablative radiation (SABR), Proton Beam Therapy (PBT), External beam radiation therapy (EBRT), Intensity - modulated radiation therapy (IMRT), Volumetric arc therapy (VMAT), Image - guided radiation therapy (IGRT)

The endocannabinoid system regulates energy homeostasis through G protein — coupled cannabinoid - 1 receptors5, 6 located in the central nervous system and in various peripheral tissues, including adipose tissue, muscle, the gastrointestinal tract, and the liver.7 While peripheral cannabinoid - 1 receptor activation decreases adiponectin production in adipocytes, 8 central cannabinoid - 1 receptor activation in preclinical studies stimulates eating, decreases muscle, and stimulates hepatic and adipose tissue lipogenic pathways in animal models of obesity.9 In genetic and diet - induced obesity, rimonabant, a selective cannabinoid - 1 receptor blocker, reduces overactivation of the central8, 10 and peripheral11, 12 endocannabinoid system8, 10,13 and prevents weight gain and associated metabolic disorders, thus revealing a novel strategy for the treatment of obesity and related cardiometabolic disorders.

4 Thompson, P.D., et al. «Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease a statement... continue Regular exercise such as running increases Brain Derived Neurotrophic Factor (BDNF), which regulates the development and plasticity of the central nervous system, although the benefit may be lower in women compared with men.

Phenibut is a central nervous system depressant with anxiolytic (anti anxiety) and sedative effects which is used for the treatment of anxiety, insomnia, and a variety of other indications in some countries.

The goal of treatment for your dog is to stabilize the central nervous system, minimize any damage to the heart and decontaminate their digestive tract, in that order.

The Animal Neurology & Imaging Center is dedicated to providing exceptional patient and client care via comprehensive, state - of - the - art diagnostics and treatments for small animals with disorders of the central and peripheral nervous systems.

Treatment of fungal infections, particularly of the central nervous system and urinary tract Treatment of yeast infections of the skin and ringworm Fewer side effects than other antifungal agents, although expensive What dogs / cats should not take this medication?

Partner with board - certified specialists in Cornell's neurology services when your patients» lives - and the quality of their lives; - depend on access to state - of - the - art technology, novel treatment strategies, and board - certified specialists who are dedicated to diagnosing, treating, and rehabilitating all categories of disease involving the central and peripheral nervous systems.

Other exclusion criteria were pregnancy and current use of medications or any history of a medical condition that might affect the central nervous system at the time of scanning (eg, current treatment with a β - blocker or analgesic medication or history of head trauma with loss of consciousness or epilepsy).

EMDR therapy as a treatment, is unique because it facilitates the processing of trauma information that has become «stuck» in the central nervous system.

None of the patients had been treated with medications acting on the central nervous system (including psychiatric treatments) and none of them was receiving prophylactic medications for migraine.